In recent years new diagnostic methods have been developed, based on the detection and quantification of the PCA3 gene. PCA3 is a prostate cancer-specific gene as it is only produced by cells that have undergone transformation to prostate cancer.
The main advantage of measuring this molecular marker is that the result of this analysis is not affected by non-cancerous prostate diseases such as Benign Prostatic Hyperplasia (BPH) or Prostatitis.
With a simple urine sample prostate cancer can be identified at an early stage
This test offers up to 92% in diagnostic accuracy for prostate cancer
Prostate cancer screening with PSA blood test and digital rectal examination (DRE) is 24-37% (1).
This is because PSA is a protein normally produced by prostate cells; an elevated level in the blood serum is merely an indicator of inflammation of the prostate tissue, which does not necessarily mean cancer.
ProstaGEN
- Digital and in-app reporting